Literature DB >> 20182045

Neuroinflammation in Alzheimer's disease: mechanisms, pathologic consequences, and potential for therapeutic manipulation.

Kenneth Hensley1.   

Abstract

The concept of neuroinflammation has evolved over the past two decades from an initially controversial viewpoint to its present status as a generally accepted idea whose mechanisms and consequences are still actively under research and debate, particularly with regard to Alzheimer's disease (AD). This review summarizes the current status of neuroinflammation research as it specifically relates to AD. Neuroinflammation is discussed mechanistically with emphasis on the role of redox signal transduction linked to the activation of central nervous system-relevant innate immune pathways. Redox signaling is presented both as a causal factor and a consequence of sustained neuroinflammation. Functional relationships are discussed that connect distinct neuroinflammatory components such as cytokines, eicosanoids, classic AD pathology (amyloid plaques and neurofibrillary tangles), and the recently emergent notion of "damage-associated molecular patterns". The interaction of these paracrine factors likely can produce positive as well as negative effects on the AD brain, ranging from plaque clearance by microglia in the short term to glial dysfunction and neuronal compromise if the neuroinflammation is chronically sustained and unmitigated. Recent disappointments in AD clinical trials of anti-inflammatory drugs are discussed with reference to possible explanations and potential avenues for future pharmacological approaches to the disease.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20182045      PMCID: PMC3792565          DOI: 10.3233/JAD-2010-1414

Source DB:  PubMed          Journal:  J Alzheimers Dis        ISSN: 1387-2877            Impact factor:   4.472


  95 in total

Review 1.  Nitric oxide-sensitive guanylyl cyclase: structure and regulation.

Authors:  Doris Koesling; Michael Russwurm; Evanthia Mergia; Florian Mullershausen; Andreas Friebe
Journal:  Neurochem Int       Date:  2004-11       Impact factor: 3.921

2.  Chemotactic-like receptors and Abeta peptide induced responses in Alzheimer's disease.

Authors:  D Lorton; J Schaller; A Lala; E De Nardin
Journal:  Neurobiol Aging       Date:  2000 May-Jun       Impact factor: 4.673

3.  p38 kinase is activated in the Alzheimer's disease brain.

Authors:  K Hensley; R A Floyd; N Y Zheng; R Nael; K A Robinson; X Nguyen; Q N Pye; C A Stewart; J Geddes; W R Markesbery; E Patel; G V Johnson; G Bing
Journal:  J Neurochem       Date:  1999-05       Impact factor: 5.372

4.  Interleukin-6 and alpha-2-macroglobulin indicate an acute-phase state in Alzheimer's disease cortices.

Authors:  J Bauer; S Strauss; U Schreiter-Gasser; U Ganter; P Schlegel; I Witt; B Yolk; M Berger
Journal:  FEBS Lett       Date:  1991-07-08       Impact factor: 4.124

5.  Intracranially administered anti-Abeta antibodies reduce beta-amyloid deposition by mechanisms both independent of and associated with microglial activation.

Authors:  Donna M Wilcock; Giovanni DiCarlo; Debbi Henderson; Jennifer Jackson; Keisha Clarke; Kenneth E Ugen; Marcia N Gordon; Dave Morgan
Journal:  J Neurosci       Date:  2003-05-01       Impact factor: 6.167

6.  Interleukin-1 gene cluster polymorphisms and risk of Alzheimer's disease in Chinese Han population.

Authors:  X-Q Li; J-W Zhang; Z-X Zhang; D Chen; Q-M Qu
Journal:  J Neural Transm (Vienna)       Date:  2004-05-12       Impact factor: 3.575

7.  Cholinergic protection via alpha7 nicotinic acetylcholine receptors and PI3K-Akt pathway in LPS-induced neuroinflammation.

Authors:  Ethika Tyagi; Rahul Agrawal; Chandishwar Nath; Rakesh Shukla
Journal:  Neurochem Int       Date:  2009-09-23       Impact factor: 3.921

Review 8.  Nox proteins in signal transduction.

Authors:  David I Brown; Kathy K Griendling
Journal:  Free Radic Biol Med       Date:  2009-07-21       Impact factor: 7.376

9.  Increased cytotoxic potential of microglia from ALS-transgenic mice.

Authors:  Patrick Weydt; Eric C Yuen; Bruce R Ransom; Thomas Möller
Journal:  Glia       Date:  2004-11-01       Impact factor: 7.452

10.  Distribution of interleukin-1-immunoreactive microglia in cerebral cortical layers: implications for neuritic plaque formation in Alzheimer's disease.

Authors:  J G Sheng; W S Griffin; M C Royston; R E Mrak
Journal:  Neuropathol Appl Neurobiol       Date:  1998-08       Impact factor: 8.090

View more
  84 in total

1.  Polyadenylation of nascent RNA during the embryogenesis of Ilyanassa obsoleta.

Authors:  J R Collier
Journal:  Exp Cell Res       Date:  1975-10-15       Impact factor: 3.905

2.  Anti-inflammatory Function of Phyllostachys Edulis Extract in the Hippocampus of HIV-1 Transgenic Rats.

Authors:  Xiaosha Pang; Jun Panee
Journal:  J HIV AIDS       Date:  2016-05-11

3.  Presenilin 2 influences miR146 level and activity in microglia.

Authors:  Suman Jayadev; Amanda Case; Betty Alajajian; Alison J Eastman; Thomas Möller; Gwenn A Garden
Journal:  J Neurochem       Date:  2013-09-30       Impact factor: 5.372

Review 4.  Microglial priming in Alzheimer's disease.

Authors:  Jun-Wei Li; Yu Zong; Xi-Peng Cao; Lin Tan; Lan Tan
Journal:  Ann Transl Med       Date:  2018-05

Review 5.  The choreography of neuroinflammation in Huntington's disease.

Authors:  Andrea Crotti; Christopher K Glass
Journal:  Trends Immunol       Date:  2015-05-20       Impact factor: 16.687

6.  Activation of Hippocampal CREB by Rolipram Partially Recovers Balance Between TNF-α and IL-10 Levels and Improves Cognitive Deficits in Diabetic Rats.

Authors:  Ya Miao; Ting He; Yitong Zhu; Wei Li; Beiyuan Wang; Yuan Zhong
Journal:  Cell Mol Neurobiol       Date:  2015-05-23       Impact factor: 5.046

7.  Multi-faceted therapeutic strategy for treatment of Alzheimer's disease by concurrent administration of etodolac and α-tocopherol.

Authors:  Khaled H Elfakhri; Ihab M Abdallah; Andrew D Brannen; Amal Kaddoumi
Journal:  Neurobiol Dis       Date:  2019-01-30       Impact factor: 5.996

8.  A Novel Angiotensin-(1-7) Glycosylated Mas Receptor Agonist for Treating Vascular Cognitive Impairment and Inflammation-Related Memory Dysfunction.

Authors:  Meredith Hay; Robin Polt; Michael L Heien; Todd W Vanderah; Tally M Largent-Milnes; Kathleen Rodgers; Torsten Falk; Mitchell J Bartlett; Kristian P Doyle; John P Konhilas
Journal:  J Pharmacol Exp Ther       Date:  2019-02-01       Impact factor: 4.030

9.  Ginsennoside rd attenuates cognitive dysfunction in a rat model of Alzheimer's disease.

Authors:  Juanfang Liu; Xiaodong Yan; Ling Li; Yi Zhu; Kefeng Qin; Linfu Zhou; Dong Sun; Xiaohui Zhang; Ruidong Ye; Gang Zhao
Journal:  Neurochem Res       Date:  2012-08-18       Impact factor: 3.996

10.  Neuroprotective effects of resveratrol against Aβ administration in rats are improved by lipid-core nanocapsules.

Authors:  Rudimar L Frozza; Andressa Bernardi; Juliana B Hoppe; André B Meneghetti; Aline Matté; Ana M O Battastini; Adriana R Pohlmann; Sílvia S Guterres; Christianne Salbego
Journal:  Mol Neurobiol       Date:  2013-01-12       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.